AstraZeneca sues FDA over cholesterol drug

AstraZeneca has sued the US Food and Drug Administration (FDA), asking a court to prevent the FDA from approving any generic version of Crestor (rosuvastatin), which is due to expire on July 8 this year.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.

Americas

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

4 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.

Americas

Brussels under scrutiny for IP policy as US flags risks to innovation

1 May 2026 The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.